Subscribe to press release roundup

To regularly receive important releases about Endeavour Vision and portfolio companies

Title *
First name *
Last name *
E-mail *
 
July 31, 2013
Merz Pharma takes over Swiss dermatology specialist Neocutis

 
July 8, 2013
OncoEthix Closes 18 Million CHF (~US$19 Million) Series B Financing

 
June 22, 2013
New Data Demonstrate Simple Insulin Delivery Device Can Significantly Reduce Barriers to Insulin Treatment Among People with Type 2 Diabetes

 
April 22, 2013
BIND Therapeutics and AstraZeneca Announce Worldwide Development and Commercialization Agreement for Cancer Nanomedicine

 
April 3, 2013
BIND Therapeutics Announces Global Collaboration with Pfizer to Develop and Commercialize Multiple Accurins

 
February 28, 2013
CeQur Announces Positive Results from Study Evaluating Simple Insulin Delivery Device Among People with Type 2 Diabetes

 
January 17, 2013
Molecular Partners Announces Publication of Results from a Phase I/II Clinical Trial of its

 
January 8, 2013
BIND Biosciences and Amgen Sign Agreement For The Worldwide Development and Commercialization of a Kinase Inhibitor Nanomedicine

 
November 27, 2012
CeQur Receives CE Mark for PaQ® Insulin Delivery Device

 
November 12, 2012
Molecular Partners enters into a strategic collaboration agreement with Boehringer Ingelheim to support its proprietary pipeline with clinical supply of DARPin® molecules

 
October 22, 2012
Symetis ACURATE TF™ FIM Trial Completed

 
September 26, 2012
CeQur Completes Study Evaluating Ability of Simple Insulin Delivery Device to Replace Insulin Injections Among People with Type 2 Diabetes

 
September 20, 2012
BIND Is Granted Five U.S. Patents Covering BIND-014 and Accurin(TM) Platform

 
August 21, 2012
Allergan and Molecular Partners Enter into Exclusive Alliance

 
July 25, 2012
Nfocus Neuromedical, Inc. Announces Positive One-Year Follow-Up Results from Clinical Study of Luna(TM) Aneurysm Embolization System

 
July 16, 2012
BIND Biosciences appoints Andrew J. Hirsch as Chief Financial Officer

 
June 22, 2012
BIND Biosciences CEO Scott Minick and Founder Omid Farokhzad Win Ernst & Young New England Entrepreneur of the Year Award

 
June 16, 2012
Clinical Study begins on Insulin Delivery Device for Type 2s

 
June 15, 2012
OncoEthix In-Licenses OTX015, an anticancer Bromodomain inhibitor from Mitsubishi Tanabe Pharma Corporation

 
May 31, 2012
Molecular Partners AG strengthens management team with the appointment of Lisa Rojkjaer, MD as Chief Medical Officer

 
May 15, 2012
PneumRx, Inc. Receives FDA Approval to Commence Pivotal Clinical Trial of RePneu Lung Volume Reduction Coil (RePneu LVRC) System

 
April 4, 2012
BIND Biosciences Presents Clinical Data on BIND-014 Promising Anti-tumor Effects in Patients with Advanced or Metastatic Cancers

 
January 27, 2012
Daniel Bertholet of Endeavour Vision speaks at SECA event

 
December 8, 2011
Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc. in Immunology to Develop Multispecific DARPins®

 
October 27, 2011
BIND Announces New $47.25 Million Financing To Accelerate Multi-Product Pipeline

 
September 30, 2011
Symetis’ ACURATE TA™ Aortic Bioprosthesis Receives CE Mark Certification on Sept. 30th 2011

 
May 18, 2011
Symetis reports on its trans-apical ACURATE TA™ clinical

 
May 4, 2011
Allergan and Molecular Partners enter into an exclusive license agreement for MP0112 for the treatment of retinal diseases

 
April 28, 2011
Molecular Partners reports positive results from its first clinical studies

 
April 6, 2011
BIND Biosciences Receives 2011 Edison Award

 
February 15, 2011
Nfocus Neuromedical, Inc. Luna™ Aneurysm Embolization System Receives CE Mark

 
February 11, 2011
BIND Biosciences featured in the London Times

 
February 8, 2011
Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc. in Immunology to Develop Multispecific DARPins®

 
January 7, 2011
BIND Biosciences Initiates Phase 1 Clinical Study of BIND-014

 
January 4, 2011
PneumRx, Inc. Raises $33 Million in Capital

 
November 15, 2010
Endotis Pharma reports successful completion of the neutralization study of the anticoagulant EP217609 by avidin in healthy subjects

 
October 7, 2010
Symetis closes CHF 25 million financing led by Endeavour Vision and NBGI Ventures, Eric Milledge appointed Chairman of the Board

 
September 1, 2010
Molecular Partners selected as Technology Pioneer 2011 by the World Economic Forum

 
June 29, 2010
BIND Biosciences Secures $12.4 Million Financing

 
June 2, 2010
Kuros completes patient recruitment in Phase IIb study of KUR-113 in patients with tibial shaft fractures

 
March 15, 2010
Kuros meets primary efficacy endpoint in Phase IIb study with KUR-111

 
December 15, 2009
Molecular Partners Secures CHF 46 Million in a Series B Financing

 
October 7, 2009
CeQur SA Appoints Eric Milledge Chairman of the Board of Directors

 
August 27, 2009
Lumavita AG announces Marketing Authorisation for Pentamycin in Switzerland

 
August 12, 2009
Kuros announces encouraging Phase IIa data with KUR-212 in patients with burns requiring mesh grafting

 
July 13, 2009
NovImmune successfully completes NI-0801 Phase I clinical study

 
July 7, 2009
Kuros starts Phase IIb clinical trial with DUR-211 for diabetic foot ulcers

 
June 18, 2009
Lumavita AG announces new funding

 
June 8, 2009
Kuros Completes patient recruitment in a phase IIb trial of KUR-111 in patients with tibal plateau fractures

 
May 19, 2009
Endotis Pharma reports successful completion of phase I program with EP42675, a first in class synthetic parenteral anticoagulant

 
May 12, 2009
NovImmune completes CHF 62.5 (USD 54.8) million equity financing to move portfolio forward and reacquire product rights to lead antibodies

 
March 24, 2009
Lumavita AG announces receipt of Preliminary Approval for Marketing Authorisation of pentamycin in Switzerland for the treatment of

 
February 27, 2009
Novalar Announces the Launch of OraVerse™ the First Dental Anesthesia Reversal Agent

 
January 5, 2009
CeQur SA Completes Series A Investment with 10 Million Dollar Raise in December 2009

 
September 23, 2008
Kuros and Aeris Announce Exclusive License Agreement in the Field of Lung Volume Reduction

 
September 8, 2008
Pall Corporation Acquires Molecular Diagnostics Manufacturer GeneSystems

 
January 23, 2008
Endotis Pharma Raises €25 million in a Second Financing Round

 
January 15, 2008
Molecular Partners AG collaborates with Centocor Research & Development, Inc.

 
August 14, 2007
Molecular Partners Raises 18.5 Mio CHF in Series A Financing

 
February 22, 2007
Allergan announces its acquisition of Endoart

 
February 22, 2007
Kuros receives orphan drug designation for a novel fusion protein for the treatment of solitary bone cysts

 
October 30, 2006
NovImmune raises CHF 58 million in Series B Private Financing

 
Frankfurt, July 31, 2013 – Merz Pharma Group (Frankfurt am Main) today announced that it has acquired the Swiss pharmaceutical company Neocutis S.A. The acquisition of the company`s cosmeceutical skin care business strengthens Merz`s market position in the field of aesthetic dermatology.

"Neocutis is an innovative company with an excellent presence on the U.S. market, and a promising potential for development," said Philip Burchard, CEO of Merz Pharma. "This transaction is an important step to expand our U.S. business, as Neocutis products are an excellent addition to our own aesthetics portfolio." The products are particularly used as pre- and post-treatments to aesthetic procedures.

The acquisition of Neocutis reflects the company's strategy to establish itself as a leader in the field of medical and aesthetic dermatology. The U.S. is the most important market for Merz. Merz North America is an important player in aesthetics and medical dermatology, of ...

more...
© Endeavour Vision SA 2006-2017 Terms & Conditions